Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic biomarkers of response to aflibercept (Eylea) in neovascular age-related macular degeneration
2013-002124-17Phase 4Completed
- Sponsor
- IMO Foundation
- Start
- Aug 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of aflibercept in exudative macular degeneration, sponsored by IMO Foundation. Primary endpoint: Primary: correlation of VEGF pathway SNP alleles with visual acuity response at Week 52. Started Aug 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2013-002124-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002124-17.